ISRCTN36773557已完成不适用
A randomised open comparison of intravaginal APL202 (25 µg) followed by 25 µg after 4 and 8 hours versus 3 mg of dinoprostone as a vaginal tablet followed by 3 mg after 6 hours in the induction of labour in multiparous subjects
Alliance Pharmaceuticals Ltd (UK)0 个研究点目标入组 622 人开始时间: 2010年1月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 622
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Subjects, aged 18 years or over, who had at least one previous term pregnancy suitable for induction of labour with prostaglandin cervical ripening agents
- •2. Pregnancy duration of at least 37 weeks
- •3. Subjects with an unfavourable cervix defined as a Bishop Score of less than 9
- •4. Signed informed consent
排除标准
- •1. Subjects requiring insulin to control their diabetes. Subjects with controlled Type II or gestational diabetes that do not require insulin may be included.
- •2. Subjects with a multiple pregnancy
- •3. Subjects in whom oxytocic drugs are generally contraindicated or where prolonged contractions of the uterus are considered inappropriate, i.e:
- •3.1. History of caesarean section or major uterine surgery
- •3.2. Cephalopelvic disproportion
- •3.3. Foetal malpresentation
- •3.4. Clinical suspicion or definite evidence of pre-existing foetal distress
- •3.5. History of difficult labour and/or traumatic delivery
- •3.6. Grand multiparae with over 5 previous term pregnancy
- •4. Subjects with an intercurrent vaginal, systemic or ascending infection
- •5. Subjects with clinical suspicion or definite evidence of placenta praevia or unexplained vaginal bleeding during their pregnancy. Occasional spotting, considered by the investigator to be of no clinical significance concerning the use of cervical ripening agents and having a reasonable explanation (e.g. cervical ectropion, cervical polyps), is not a reason for exclusion.
- •6. Subjects with active cardiac, pulmonary, renal or hepatic disease
- •7. Subjects with abruptio placenta. Abruptio placenta in a previous pregnancy is not a reason for exclusion.
- •8. Subjects with ruptured membranes
- •9. Subjects with a known allergy to prostaglandins or other constituents of the tablets
- •10. Subjects with any contraindication to vaginal delivery (e.g. active genital herpes)
研究者
相似试验
进行中（未招募）
1 期
A RANDOMISED OPEN COMPARISON OF INTRAVAGINAL APL202 (25µg) FOLLOWED BY 25µg AFTER 4 AND 8 HOURS VERSUS 3mg of DINOPROSTONE AS A VAGINAL TABLET FOLLOWED BY 3mg AFTER 6 HOURS IN THE INDUCTION OF LABOUR IN MULTIPAROUS SUBJECTS.Pregnancy: induction of labourEUCTR2004-000108-42-GBAlliance Pharmaceuticals415
进行中（未招募）
1 期
A RANDOMISED OPEN COMPARISON OF INTRAVAGINAL APL202 (25 or 50µg) FOLLOWED BY 25µg AFTER 4 AND 8 HOURS VERSUS 3mg OF DINOPROSTONE AS A VAGINAL TABLET FOLLOWED BY 3mg AFTER 6 HOURS IN THE INDUCTION OF LABOUR IN NULLIPAROUS SUBJECTS.Pregnancy: induction of labourEUCTR2004-000107-18-GBAlliance Pharmaceuticals415
已完成
不适用
Intravaginal APL202 versus dinoprostone in the induction of labour in nulliparous subjectsInduction of labour - nulliparous subjects onlyPregnancy and ChildbirthFailed induction of labourISRCTN27617624Alliance Pharmaceuticals Ltd (UK)622
暂停
不适用
To compare the effectiveness of trans-cervical foley catheter and intravaginal Misoprostol in making the uterine cervix more favourable for induction of labourEffectiveness of trans-cervical foley catheter and intra-vaginal Misoprotol for pre induction cervical ripeningSLCTR/2008/002one
已完成
2 期
Patient Controlled Analgesia for Total Hip or Knee Arthroplastypost hip or knee arthroplasty surgery pain.Adjustment and management of infusion pumpIRCT138902023771N1Vice Chancellor for Research & Technology, Isfahan University of Medical Sciences60